⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
SLXN News
Silexion Therapeutics Corp Ordinary Shares
Form 8-K
sec.gov
SLXNW
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics Announces First Patient Successfully Dosed in Phase 2/3 Clinical Trial of SIL204 in Locally Advanced Pancreatic Cancer
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXN
SLXNW
Silexion Therapeutics Announces Exercise of Warrants
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics Reports Positive Preclinical Findings for SIL204, Demonstrating Key Mechanism for Endogenous Systemic Uptake in KRAS-Driven Cancers
globenewswire.com
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Form 8-K
sec.gov
SLXNW
SLXN
Silexion Therapeutics to Participate in September 2026 Industry and Investor Conferences
globenewswire.com
SLXN